ARTICLE | Company News

Eisai, Blaze Bioscience deal

December 14, 2015 8:00 AM UTC

Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent to visualize cancer cells during surgery. The chlorotoxin derivative was isolated from scorpion venom and suppresses growth of activated epithelial cells. It has completed a Phase II trial in patients with recurrent glioma. ...